Table 1.
The drugs significantly associated (FDR < 0.1) with the network-signature classification based on CMAP analysis
| Drug name | CMAP rank | CMAP P-value | CMAP FDR | |||
|---|---|---|---|---|---|---|
| Network signature | Expression signature | Network signature | Expression signature | Network signature | Expression signature | |
| Harmol | 1 | 61 | 4.6E-04 | 1.1 × 10−3 | 0.015 | 4.9 × 10−3 |
| Harmalol | 2 | 67 | 4.9E-04 | 1.8 × 10−3 | 0.015 | 7.1 × 10−3 |
| Brinzolamide | 3 | 95 | 5.6E-04 | 5.8 × 10−3 | 0.016 | 0.020 |
| Edrophonium chloride | 4 | 42 | 6.0E-04 | 3.6 × 10−4 | 0.017 | 1.8 × 10−3 |
| Trimethadione | 5 | 138 | 6.8E-04 | 0.035 | 0.018 | 0.101 |
| Canavanine | 6 | 39 | 7.0E-04 | 2.7 × 10−4 | 0.018 | 1.5 × 10−3 |
| Oxamniquine | 7 | 49 | 1.3E-03 | 6.0 × 10−4 | 0.025 | 2.8 × 10−3 |
| Metolazone | 8 | 59 | 1.3E-03 | 1.0 × 10−3 | 0.025 | 4.4 × 10−3 |
| Etofylline | 9 | 112 | 3.2E-03 | 0.015 | 0.048 | 0.048 |
| Harmine** | 10 | 613 | 3.6E-03 | 1.000 | 0.051 | 1.000 |
| Tetracycline | 11 | 108 | 4.0E-03 | 0.013 | 0.056 | 0.041 |
| Sotalol | 12 | 136 | 5.5E-03 | 0.033 | 0.069 | 0.096 |
| 5213008 | 13 | 55 | 6.5E-03 | 8.1 × 10−4 | 0.080 | 3.7 × 10−3 |
| Prestwick-675 | 14 | 1 | 7.3E-03 | 6.0 × 10−6 | 0.084 | 5.2 × 10−5 |
| Pirinixic acid | 15 | 21 | 8.6E-03 | 2.4 × 10−5 | 0.095 | 1.8 × 10−4 |
| Dicoumarol** | 16 | 184 | 8.8E-03 | 0.239 | 0.097 | 0.534 |
| Pentoxyverine** | 17 | 784 | 9.1E-03 | 1.000 | 0.098 | 1.000 |
| Adipiodone** | 18 | 689 | 0.010 | 1.000 | 0.100 | 1.000 |
Drugs that are not significantly associated with the expression-signature are bolded and asterisked (**).